Lyme Disease Vaccine Pushes Valneva To US Listing

 
• By Jo Shorthouse

Thomas Lingelbach talks to Scrip about Valneva’s plans for a US IPO to fund Phase III studies of its lead Lyme disease vaccine.

Tick
Ticks carrying Borrelia bacteria cause Lyme disease • Source: Shutterstock

More from Anti-infective

More from Therapy Areas